Literature DB >> 11303853

Use of endogenous ACTH concentration and adrenal ultrasonography to distinguish the cause of canine hyperadrenocorticism.

S M Gould1, E A Baines, P A Mannion, H Evans, M E Herrtage.   

Abstract

Twenty-nine dogs were diagnosed with hyperadrenocorticism (HAC). A single determination of endogenous plasma adrenocorticotropic hormone (ACTH) and adrenal ultrasonography were used in a prospective study to differentiate between pituitary-dependent HAC (PDH) and adrenal-dependent HAC (ADH). In 27 out of the 29 dogs (93 per cent), both endogenous plasma ACTH concentrations and adrenal ultrasonography indicated the same cause of HAC. Twenty-one of the 29 cases (72 per cent) were shown to be pituitary-dependent; all had plasma ACTH concentrations of greater than 28 pg/ml (reference range 13 to 46 pg/ml) and both adrenal glands were ultrasonographically of similar size and of normal shape. All 21 cases responded well to mitotane therapy. Six cases (21 per cent) were shown to be adrenal-dependent; all had plasma ACTH concentrations below the limit of the assay (<5 pg/ml) and the presence of an adrenal mass on ultrasonography. The sensitivity and specificity of adrenal ultrasonography and endogenous ACTH determinations to identify the cause of HAC were demonstrated to be 100 per cent and 95 per cent, respectively, for ADH. These discriminatory tests are more accurate than published figures for dexamethasone suppression testing.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11303853     DOI: 10.1111/j.1748-5827.2001.tb02007.x

Source DB:  PubMed          Journal:  J Small Anim Pract        ISSN: 0022-4510            Impact factor:   1.522


  7 in total

Review 1.  Diagnosis and management of geriatric canine endocrine disorders.

Authors:  A Boari; G Aste
Journal:  Vet Res Commun       Date:  2003-09       Impact factor: 2.459

2.  Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs.

Authors:  L Macfarlane; T Parkin; I Ramsey
Journal:  Vet Rec       Date:  2016-11-01       Impact factor: 2.695

3.  Comparison of Survival Times for Dogs with Pituitary-Dependent Hyperadrenocorticism in a Primary-Care Hospital: Treated with Trilostane versus Untreated.

Authors:  N Nagata; K Kojima; M Yuki
Journal:  J Vet Intern Med       Date:  2016-12-01       Impact factor: 3.333

4.  An activating mutation in the CRHR1 gene is rarely associated with pituitary-dependent hyperadrenocorticism in poodles.

Authors:  Viviani De-Marco; Luciani R Carvalho; Mariana F Guzzo; Paulo S L Oliveira; Larissa G Gomes; Berenice B Mendonca
Journal:  Clinics (Sao Paulo)       Date:  2017-10       Impact factor: 2.365

5.  Concurrent pituitary and adrenocortical lesions on computed tomography imaging in dogs with spontaneous hypercortisolism.

Authors:  Kirsten L van Bokhorst; Hans S Kooistra; Susanne A E B Boroffka; Sara Galac
Journal:  J Vet Intern Med       Date:  2018-12-11       Impact factor: 3.333

6.  Comparison of methods to monitor dogs with hypercortisolism treated with trilostane.

Authors:  Stefania Golinelli; Viviani de Marco; Rodolfo Oliveira Leal; Andrea Barbarossa; Camilla Aniballi; Elisa Maietti; Antonio Maria Tardo; Sara Galac; Federico Fracassi
Journal:  J Vet Intern Med       Date:  2021-10-21       Impact factor: 3.333

7.  Effect of trilostane on hormone and serum electrolyte concentrations in dogs with pituitary-dependent hyperadrenocorticism.

Authors:  C Griebsch; C Lehnert; G J Williams; K Failing; R Neiger
Journal:  J Vet Intern Med       Date:  2013-12-16       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.